Gilead Sciences GILD Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 314.4%+8.5pp | 305.9%-7.6pp | 313.4%+8.2pp | 305.2%-11.8pp | |
| Operating margin | 126.6%+103pp | 23.6%-98.2pp | 121.8%+21.1pp | 100.8%-32.5pp | |
| Net margin | 99.4%+91.7pp | 7.7%-75.3pp | 83%+22.4pp | 60.6%-9.7pp | |
| EBITDA margin | 131.8%+96.4pp | 35.4%-115pp | 150.8%+30.5pp | 120.2%-17.7pp | |
| Free cash flow margin | 130.3%+7.6pp | 122.7%+3.1pp | 119.6%-14.6pp | 134.2%-5.7pp | |
| Returns | |||||
| Return on equity | 146.8%+136pp | 10.7%-95.8pp | 106.6%+25.2pp | 81.3%-17.2pp | |
| Return on assets | 50.9%+47.3pp | 3.6%-32.5pp | 36.1%+10.8pp | 25.4%-4.1pp | |
| Return on invested capital | 82.3%+71.7pp | 10.6%-51.7pp | 62.2%+13.8pp | 48.4%-16.2pp | |
| Efficiency | |||||
| Asset turnover | 2.1×+0.1× | 1.9×+0.2× | 1.7×+0.1× | 1.7×0.0× | |
| Inventory turnover | 12.9×-4.2× | 17.1×-0.3× | 17.4×-4.7× | 22.1×+2.1× | |
| Liquidity | |||||
| Current ratio | 5.7×+0.6× | 5.1×0.0× | 5.1×-0.4× | 5.5×+0.1× | |
| Quick ratio | 4.9×+0.4× | 4.5×0.0× | 4.5×-0.5× | 5×+0.1× | |
| Cash ratio | 2.3×+0.5× | 1.9×0.0× | 1.9×-0.1× | 1.9×+0.2× | |
| Leverage | |||||
| Debt-to-equity | 4.9×-0.5× | 5.4×+0.7× | 4.6×-0.4× | 5×-0.7× | |
| Debt-to-assets | 1.7×0.0× | 1.8×+0.1× | 1.6×0.0× | 1.6×-0.1× | |
| Net debt / EBITDA | 7.7×-28.4× | 36.1×+28.4× | 7.7×-2.6× | 10.3×-1.7× | |
| Interest coverage | 36.5×+29.7× | 6.8×-29.1× | 35.8×+7.1× | 28.8×-6.6× | |
| Per Share | |||||
| Book value per share | $66.16+12.5% | $58.81-15.2% | $69.37+6.1% | $65.40+1.6% | |
| Valuation | |||||
| Market capitalization | $563.05B+42.1% | $396.23B+0.5% | $394.07B+16.9% | $337.18B-2.6% | |
| Enterprise value | $635.46B+34.4% | $472.82B0.0% | $472.76B+12.2% | $421.49B-4.8% | |
| Price / earnings | 79.4×-1,259× | 1,338×+1,268× | 69.8×-12.1× | 81.9×-231× | |
| Price / sales | 19.4×+5.3× | 14.1×-0.4× | 14.5×+2.1× | 12.3×-0.6× | |
| Price / book | 27.2×+5.7× | 21.5×+3.4× | 18.1×+1.8× | 16.3×-0.8× | |
| EV / EBITDA | 67.1×-166× | 232.9×+187× | 46.1×-5.0× | 51.1×-2.3× | |
| EV / sales | 21.9×+5.1× | 16.8×-0.5× | 17.4×+2.0× | 15.4×-1.1× | |
| Free cash flow yield | 26.9%-7.8pp | 34.7%+1.6pp | 33.1%-11.7pp | 44.9%+1.6pp | |
| Earnings yield | 20.5%+18.2pp | 2.3%-20.7pp | 23%+3.0pp | 20%-1.7pp | |
| Dividend yield | 11.3%-4.5pp | 15.8%+0.5pp | 15.3%-2.5pp | 17.8%+1.4pp | |
| PEG ratio | 0.1×— | —— | 2.3×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Gilead Sciences's profit margins?
- Gilead Sciences (GILD) runs a 79.4% gross margin and a 34.9% operating margin, with a 31.0% net margin.
- Where do Gilead Sciences's ratios come from?
- Every ratio is computed from Gilead Sciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
